

EMLc

Codes ATC: J01CF02

Indication	Sepsis without septic shock Code ICD11: 1G40
INN	Cloxacillin
Type de médicament	Chemical agent
Groupes d'antibiotiques	 ACCESS
Type de liste	Liste de base (EML) (EMLc)
Additional notes	*cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability
Formulations	Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid (EMLc) ; 250 mg per 5 mL (as sodium salt) powder for oral liquid (EMLc) Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection (EMLc) ; 250 mg in vial (as sodium salt) powder for injection (EMLc) Oral > Solid > capsule: 500 mg (as sodium salt) (EMLc) ; 1 g (as sodium salt) (EMLc) ; 250 mg (as sodium salt) (EMLc)
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2021 (TRS 1035) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Enfants (1 mois - 12 ans)
Équivalence thérapeutique	Des médicaments appartenant à la même classe pharmacologique peuvent être utilisés
Limites de l'équivalence thérapeutique	Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: J01CF Beta-lactamase resistant penicillins.
Limites d'équivalence thérapeutique pour l'EMLc	Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: J01CF Beta-lactamase resistant penicillins.
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets . 
Wikipédia	Cloxacillin 
DrugBank	Cloxacillin 

Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as

sulfate) in 2 mL vial) to the EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.

Recommandations de la LME : Sepsis without septic shock

Premier choix

gentamicin

co-prescrite avec [amoxicillin](#)

gentamicin

co-prescrite avec [ampicillin](#)

gentamicin

co-prescrite avec [benzylpenicillin](#)

Second choix

cefotaxime

ceftriaxone

cloxacillin

co-prescrite avec [amikacin](#)

